You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR THALITONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for THALITONE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00591773 ↗ Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension Completed Takeda Phase 3 2007-09-01 The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.
NCT01203852 ↗ Pharmacogenomic Evaluation of Antihypertensive Responses 2 Completed National Institute of General Medical Sciences (NIGMS) Phase 4 2010-08-01 There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
NCT01203852 ↗ Pharmacogenomic Evaluation of Antihypertensive Responses 2 Completed University of Florida Phase 4 2010-08-01 There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
NCT02030314 ↗ The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone Withdrawn Virginia Commonwealth University Phase 4 2013-07-01 Chlorthalidone might offer an effective, safe and inexpensive anti-hypertensive treatment for kidney transplant patients who have resistant hypertension on multi-drug therapy. We will collect initial data on the safety and efficacy of Chlorthalidone in the treatment of patients with resistant hypertension. To Examine the efficacy of chlorthalidone as an anti-hypertensive agent in the treatment of resistant hypertension among stable kidney transplant recipients
NCT02121041 ↗ Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study Completed North Carolina Translational and Clinical Sciences Institute N/A 2014-05-01 The purpose of this study is to compare the effectiveness of ambulatory blood pressure monitoring to usual care (blood pressure measurement in the office) in diagnosing and managing hypertension.
NCT02121041 ↗ Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study Completed Anthony J Viera, MD, MPH N/A 2014-05-01 The purpose of this study is to compare the effectiveness of ambulatory blood pressure monitoring to usual care (blood pressure measurement in the office) in diagnosing and managing hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for THALITONE

Condition Name

Condition Name for THALITONE
Intervention Trials
Hypertension 3
Resistant Hypertension in Kidney Transplant Patients 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for THALITONE
Intervention Trials
Hypertension 4
Essential Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for THALITONE

Trials by Country

Trials by Country for THALITONE
Location Trials
United States 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for THALITONE
Location Trials
Virginia 2
North Carolina 2
Florida 2
Minnesota 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for THALITONE

Clinical Trial Phase

Clinical Trial Phase for THALITONE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for THALITONE
Clinical Trial Phase Trials
Completed 3
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for THALITONE

Sponsor Name

Sponsor Name for THALITONE
Sponsor Trials
Anthony J Viera, MD, MPH 1
Takeda 1
National Institute of General Medical Sciences (NIGMS) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for THALITONE
Sponsor Trials
Other 4
Industry 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.